Answers are grounded in this paper and cite their sources.
In the field of peripheral artery disease (PAD), regenerative cell therapy has been expected to be a new alternative therapy especially for severely diseased patients. Although various preclinical studies showed promising results, those therapies failed to show sufficient efficacy for actual PAD patients and current guideline do not recommend regenerative therapy for PAD. The disappointing result may be caused by low retention rate of administered substance. Recently we published an article regarding novel method to augment the effect of cell therapy. In this review article, we would like to focus on the importance of improvement in cell survival and prerequisite factors to develop effective regenerative therapy for PAD patients.
No takes yet. Share an insight, caveat, or question.
Miyake et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: